A phase III, open-label, single-arm, study to evaluate the safety and immunogenicity of a trivalent, surface antigen inactivated subunit influenza virus vaccine produced in mammalian cell culture (Optaflu®) in healthy adults
Loebermann, Micha, Fritzsche, Carlos, Geerdes-Fenge, Hilte, Heijnen, Esther, Kirby, Daniel, Reisinger, Emil C.Language:
english
Journal:
Infection
DOI:
10.1007/s15010-018-1233-2
Date:
October, 2018
File:
PDF, 764 KB
english, 2018